

Can't find or afford Veozah? Here are the best alternatives for menopause hot flashes in 2026, including nonhormonal and hormonal options.
If you've been prescribed Veozah (Fezolinetant) for menopause hot flashes but can't fill your prescription — whether because your pharmacy doesn't have it, your insurance won't cover it, or the cost is too high — you have options.
Pro tip: Before switching medications, try Medfinder to check if a pharmacy near you has Veozah in stock. Sometimes the solution is finding the right pharmacy, not a different medication.
But if you do need an alternative, here's what you and your doctor should consider.
Veozah is a nonhormonal prescription medication approved by the FDA in May 2023 for the treatment of moderate to severe vasomotor symptoms (VMS) — hot flashes and night sweats — due to menopause. It contains the active ingredient Fezolinetant and belongs to a new class of drugs called NK3 receptor antagonists.
Veozah is manufactured by Astellas Pharma and is taken as a 45 mg tablet once daily. It's currently only available as a brand-name medication with no generic version, which contributes to its high cash price of $550–$765 per month.
To understand your alternatives, it helps to understand how Veozah works in the first place.
During menopause, your estrogen levels drop. This creates an imbalance with a brain chemical called neurokinin B (NKB), which plays a key role in your body's temperature regulation. When NKB is overactive without enough estrogen to balance it, your brain's thermostat essentially misfires — triggering the sudden waves of heat, sweating, and flushing that we call hot flashes.
Veozah works by blocking the NK3 receptor in the brain's thermoregulatory center. By preventing NKB from binding to this receptor, Veozah restores the balance and reduces both the frequency and severity of hot flashes — all without adding hormones to your system.
This is important because not all women can or want to take hormones. Women with a history of breast cancer, blood clots, or certain other conditions may need nonhormonal options.
The following medications are used to treat menopause hot flashes and may be appropriate alternatives depending on your medical history, preferences, and insurance coverage. Always consult with your healthcare provider before making any changes to your medication.
Lynkuet is the newest option on the market. It was FDA approved in October 2025 and became available in the U.S. in November 2025. Like Veozah, it's a nonhormonal treatment — but with a key difference.
Brisdelle is the only other FDA-approved nonhormonal medication specifically indicated for moderate to severe VMS due to menopause.
Estrogen-based hormone therapy remains the most effective treatment for menopause hot flashes for women who can safely take it.
Several medications approved for other conditions are used off-label to treat hot flashes:
These off-label options are generally less expensive than Veozah and may be covered more easily by insurance.
If you can't find or afford Veozah, you still have real options for managing menopause hot flashes. The best alternative depends on your medical history, other medications you take, and your personal preferences.
Before switching, try Medfinder to see if Veozah is available at a pharmacy near you. And check out our guide on how to find Veozah in stock for more tips.
For information on lowering your costs, see how to save money on Veozah in 2026. And to learn more about how Veozah works in your body, read our article on Veozah's mechanism of action explained.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.